ARV-393 | MedChemExpress (MCE)

ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC₅₀ and GI₅₀ values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma.

Price Not Available 25 mg ARV-393 | MedChemExpress (MCE) Supplier Page

Trivial name	ARV-393
Catalog Number	HY-158105
Research Area	Cancer
CAS#	2851885-95-3
Purity	≥98.0%
SMILES	ClC1=CN=C(N2CCC(O[C@@H]3C[C@@H](N4CCC(C5=C(F)C(CN(C6CCC(NC6=O)=O)C7=O)=C7C=C5)CC4)C3)CC2)N=C1NC8=CC(C=C(OCC(NC)=O)C(N9C(C)C)=O)=C9C=C8
Size	25 mg
Supplier Page	https://www.medchemexpress.com/arv-393.html